VERONA PHARMA P/S (VRNA) Expected to Post Earnings of -$0.49 Per Share

Share on StockTwits

Brokerages expect that VERONA PHARMA P/S (NASDAQ:VRNA) will announce earnings of ($0.49) per share for the current quarter, Zacks reports. Zero analysts have made estimates for VERONA PHARMA P/S’s earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.41). VERONA PHARMA P/S posted earnings of ($0.91) per share in the same quarter last year, which suggests a positive year over year growth rate of 46.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, November 6th.

Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover VERONA PHARMA P/S.

VERONA PHARMA P/S (NASDAQ:VRNA) last posted its earnings results on Tuesday, August 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $1.20.

A number of research firms have weighed in on VRNA. Jefferies Financial Group reaffirmed a “buy” rating and set a $26.00 target price on shares of VERONA PHARMA P/S in a research note on Friday, August 10th. Zacks Investment Research raised shares of VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 target price on the stock in a research note on Friday, August 24th. ValuEngine raised shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research note on Monday, June 11th. Finally, Wedbush set a $56.00 target price on shares of VERONA PHARMA P/S and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $31.33.

An institutional investor recently raised its position in VERONA PHARMA P/S stock. Foresite Capital Management III LLC increased its holdings in VERONA PHARMA P/S (NASDAQ:VRNA) by 7.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 565,292 shares of the company’s stock after purchasing an additional 36,870 shares during the quarter. VERONA PHARMA P/S makes up 2.5% of Foresite Capital Management III LLC’s investment portfolio, making the stock its 12th biggest holding. Foresite Capital Management III LLC owned approximately 4.31% of VERONA PHARMA P/S worth $11,306,000 as of its most recent SEC filing. Institutional investors and hedge funds own 49.47% of the company’s stock.

Shares of NASDAQ VRNA traded down $0.60 during midday trading on Thursday, reaching $12.50. 8,191 shares of the company were exchanged, compared to its average volume of 2,289. VERONA PHARMA P/S has a one year low of $10.44 and a one year high of $25.55.

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Featured Story: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on VERONA PHARMA P/S (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.